AveXis Obtains $65,000,000 Series D Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=526780e4-f089-4300-a11b-595c17df3fe0 - Date
9/9/2015 - Company Name
AveXis - Mailing Address
4925 Greenville Avenue Dallas, TX 75206 USA - Company Description
AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus. - Website
http://www.avexisinc.com - Transaction Type
Venture Equity - Transaction Amount
$65,000,000 - Transaction Round
Series D - Proceeds Purposes
The proceeds will be used to advance the company’s ongoing spinal muscular atrophy (SMA) clinical program and expand key operational capabilities. - M&A Terms
- Venture Investor
T. Rowe Price - Venture Investor
Deerfield Capital - Venture Investor
Roche Venture Fund - Venture Investor
Venrock - Venture Investor
Janus Capital - Venture Investor
Adage Capital Management - Venture Investor
RA Capital - Venture Investor
QVT Fund - Venture Investor
Rock Springs Capital - Venture Investor
Foresite Capital - Venture Investor
Tavistock Life Sciences
